US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options.

The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy.

Brepocitinib has generated positive data in seven phase 2 studies with oral once-daily administration. It is currently being evaluated in a phase 3 program for dermatomyositis and is entering a phase 3 program for non-infectious uveitis.

This week on the podcast we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how brepocitinib is making a difference.

00:55-02:34: About Priovant
02:34-06:38: What are dermatomyositis and non-infectious uveitis?
06:38-08:35: What are the current treatments?
08:35-12:32: What is brepocitinib?
12:32-15:36: Are there other treatments in development?
15:36-17:50: What is your relationship with Pfizer?
17:50-20:48: Brepocitinib clinical trials
20:48-24:06: Future plans and timeline
24:06-27:59: Finding patients for clinical trials
27:59-29:19: Future opportunities

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Episode 17 - The Eyes Have It (Part II)